On August 20, WUXI XDC rose 4.04% in regular trading, trading at 68.9 HKD/share, with turnover of approximately 97.46 million HKD.

On the news front, the company recently announced that its Singapore-based BCM3 dual-function production line for antibody intermediates and drug substance has successfully completed GMP release, marking a new phase in its global capacity expansion. BCM3 will work in coordination with the Wuxi-based BCM1 and BCM2 lines to achieve a substantial leap in production capacity, while the formulation line DP4 is expected to complete GMP release by end of August.

Additionally, the company is scheduled to hold a board meeting on August 24 to review interim results. Fellow WuXi-platform company WuXi AppTec reported H1 revenue growth of 38.93% year-over-year and net profit growth of 29.43%, while fully raising full-year guidance, continuing to boost sector sentiment. Institutional activity also remains supportive, with Schroders PLC having increased its long position to 5.01% earlier this month.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)